Symplicity HTN-3 trial: What is it andwhat does it mean?

European Heart Journal

Volumn 35, Issue 26, 2014, Pages 1697-1698

  Böhm, Michael ^a   Mahfoud, Felix ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DARUSENTAN; PLACEBO; SPIRONOLACTONE; VASODILATOR AGENT;

AFRICAN AMERICAN; CATHETER; CAUCASIAN; CLINICAL EFFECTIVENESS; DEVICE SAFETY; END STAGE RENAL DISEASE; FOLLOW UP; HUMAN; HYPERTENSIVE CRISIS; KIDNEY ARTERY STENOSIS; KIDNEY DENERVATION; NOTE; PATHOPHYSIOLOGY; PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL ARTERY; RENAL DENERVATION SYSTEM; RESISTANT HYPERTENSION; SHAM PROCEDURE; SYSTOLIC BLOOD PRESSURE; TREATMENT FAILURE; WHITE COAT HYPERTENSION; HYPERTENSION; INNERVATION; KIDNEY; PROCEDURES; SYMPATHECTOMY;

HUMANS; HYPERTENSION; KIDNEY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SYMPATHECTOMY;

EID: 84921351304     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu215     Document Type: Note

References (16)

1. Bhatt DL, Kandzari DE,O'NeillWW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL. The Symplicity HTN-3 Investigators.A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014 (Epub ahead of print).
2. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, AbrahamWT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373:1275-1281.
3. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet 2010;376:1903-1909.
4. Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 2014;383: 622-629.
5. Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA. Symplicity HTN-2 Investigators. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation 2012;126:2976-2982.
6. Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, Papademetriou V. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J 2013;34:2132-2140.
7. Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, Linseman JV, Wiens BL, Warren MS, Lindholm LH. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1423-1431.
8. Bakris GL, Lindholm LH, Black HR, Krum H, Linas S, Linseman JV, Arterburn S, Sager P, Weber M. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension 2010; 56:824-830.
9. Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens 2013;31:2094-2102.
10. Gould BA, Mann S, Davies AB, Altman DG, Raftery EB. Does placebo lower bloodpressure? Lancet 1981;2:1377-1381.
11. O'Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, Clement D, de la Sierra A, de Leeuw P, Dolan E, Fagard R, Graves J, Head GA, Imai Y, Kario K, Lurbe E, Mallion JM, Mancia G, Mengden T, Myers M, Ogedegbe G, Ohkubo T, Omboni S, Palatini P, Redon J, Ruilope LM, Shennan A, Staessen JA, van Montfrans G, Verdecchia P,Waeber B,Wang J, Zanchetti A, Zhang Y. European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 2013; 31:1731-1768.
12. Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, Weil J, Schmidt M, Hoppe UC, Zeller T, Bauer A, Ott C, Blessing E, Sobotka PA, Krum H, Schlaich M, Esler M, Böhm M. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 2013;128: 132-140.
13. Böhm M, Mahfoud F, Ukena C, Hoppe UC, Narkiewicz K, Negoita M, Ruilope L, Schlaich M, Schmieder M, Whitbourn R, Williams B, Zeymer U, Zirlik A, Mancia G. Effect of renal denervation in a real world population of patients with uncontrolled hypertension - the GLOBAL SYMPLICITY registry. Late Breaking Clinical Trials, Am Coll Cardiol, Washington, 2014;00:00-00.
14. Böhm M, Linz D, Urban D, Mahfoud F, Ukena C. Renal sympathetic denervation: applications in hypertension and beyond. Nat Rev Cardiol 2013;10:465-476.
15. Böhm M, Schumacher H, Laufs U, Sleight P, Schmieder R, Unger T, Teo K, Yusuf S. Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. Am Heart J 2013;166:306-314.
16. Messerli FH, Bangalore S. Renal denervation for resistant hypertension?NEngl J Med 2014 ;370:1454-1457.